ArticleScientific reports2025
Regulation of feeding and metabolism by fat mass and obesity-associated protein in zebrafish.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- FTO in Bone Diseases: Functions, Mechanisms and Therapeutic Potential.Biomolecules · 2026Review
- Review
- Implications of Genetic Elements on Type 2 Diabetes Mellitus Pathogenesis and Management.Endocrinology, diabetes & metabolism · 2026Review
- Recommendations of the Polish Zebrafish Society on the use of the zebrafish (Acta biochimica Polonica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fat mass and obesity-associated (FTO) gene has been widely implicated in the regulation of energy balance in mammals. Whether FTO has similar roles in non-mammals remains unexplored. The goal of this research was to determine if FTO inhibition affects feeding, metabolism and lipid homeostasis in zebrafish (Danio rerio). Rhein, a pharmacological inhibitor of FTO was used to examine if FTO suppression modulates metabolic pathways in zebrafish liver and brain in vivo, and in zebrafish liver (ZFL) cells in vitro. Rhein treatment resulted in a significant reduction in food intake, accompanied by corresponding downregulation of FTO and its downstream effector IRX3 at both the mRNA and protein levels. Inhibiting FTO upregulated lipid oxidation genes and downregulated lipogenic pathways, indicating enhanced lipid catabolism. Moreover, rhein administration elevated key metabolic regulators AMPK and PPARα while suppressing gluconeogenic genes, suggesting improved glucose homeostasis. These findings suggest that FTO plays an important role in zebrafish metabolic regulation and that its inhibition modulates energy balance via the STAT3 signaling pathway. This research provides insights into the evolutionary conservation of FTO function and further supports FTO as a key molecule in zebrafish metabolic regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.